Celgene Withdraws EU Filing For Revlimid After Second CHMP Refusal
This article was originally published in The Pink Sheet Daily
Executive Summary
Company counters setback by unveiling promising lenalidomide data from NHL, newly diagnosed multiple myeloma trials during ASCO.
You may also be interested in...
Genzyme Submits Mozobil In U.S. And Europe
Stem-cell mobilizer targets a shrinking niche market, analyst tells "The Pink Sheet" DAILY.
Genzyme Submits Mozobil In U.S. And Europe
Stem-cell mobilizer targets a shrinking niche market, analyst tells "The Pink Sheet" DAILY.
Europe Likes Schering’s Bridion, But Not Takeda’s Rozerem
New opinion includes CHMP skepticism of insomnia drug.